Inhalierte Vasodilatatoren

Zwißler, Bernhard

doi:10.1007/s00101-002-0370-1

Cited by 22 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treating pulmonary hypertension with inhaled vasodilators is an attractive concept because they cause selective intrapulmonary vasodilation [1]. When nitric oxide became available it was soon used as an inhaled vasodilator in humans [2].…”

Section: Discussionmentioning

confidence: 99%

The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy

Flondor

Merkel²,

Hofstetter

et al. 2006

Anaesthesia

Self Cite

View full text Add to dashboard Cite

SummaryAcute pulmonary hypertension with life-threatening right heart failure may complicate the postoperative course following cardiothoracic surgery. Both inhaled nitric oxide and inhaled iloprost, a stable analogue of prostacyclin, have been used frequently for this purpose in acute pulmonary hypertension of various origins. We present a case of a patient with acute pulmonary hypertension and severely impaired gas exchange following pulmonary thrombo-endarterectomy. Therapy with one inhaled vasodilator alone did not satisfactorily abort a postoperative pulmonary hypertensive crisis and low-output syndrome due to right heart failure. Combined inhaled nitric oxide and inhaled iloprost, however, showed additive effects. Hence, the combination of both drugs may be reasonable in cases where the standard therapy fails. The effect has been demonstrated by means of continuous blood gas monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy

Flondor

Merkel²,

Hofstetter

et al. 2006

Anaesthesia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Due to the rapid binding of the molecule to hemoglobin, systemic vasodilatation and hypotension should be avoided. [78–80] However, these effects are unfortunately transient and without any influence on mortality as demonstrated in recent trials. [81–83]…”

Section: Therapy Strategiesmentioning

confidence: 99%

Acute lung injury and acute respiratory distress syndrome

Ragaller

Richter

2010

J Emerg Trauma Shock

112

View full text Add to dashboard Cite

Every year, more information accumulates about the possibility of treating patients with acute lung injury or acute respiratory distress syndrome with specially designed mechanical ventilation strategies. Ventilator modes, positive end-expiratory pressure settings, and recruitment maneuvers play a major role in these strategies. However, what can we take from these experimental and clinical data to the clinical practice? In this article, we discuss substantial options of mechanical ventilation together with some adjunctive therapeutic measures, such as prone positioning and inhalation of nitric oxide.

show abstract

“…The major areas of research and therapeutic applications are asthma (Pahl and Szelenyi, 2002), cystic fibrosis (Contreras and Hickey, 2002), lung cancer (Sharma et al, 2001), tuberculosis (Suarez et al, 2001), pulmonary hypertension (Zwissler, 2002), and diabetes (Owens, 2002). As these peptides have a short life, the development of delivery systems with sustained pharmacological action would be very useful.…”

Section: Nanoparticulate Drug-delivery Systems For Pulmonary Treatmentmentioning

confidence: 99%

Nanoparticles: a boon for modernisation of drug delivery: a review

Khan

Gowda

2011

IJNP

View full text Add to dashboard Cite

In the medical field, the active ingredient is in the form of solid particles for 90% of all medicines. Because of development in nanotechnology, it is now possible to produce drug nanoparticles that can be utilised in a variety of innovative ways according to the need. From few decades, there had been considerable interest in area of nanotechnology and many works have been done in order to deliver drugs using particulate delivery systems (nanoparticles) as carriers for small and large molecules. Development of nanoparticles arose in response to vast and broad medical needs, common to a number of therapeutic areas and targets. The potential advantages of nanoparticles as oral drug carriers are enhancement of bioavailability, delivery of vaccine antigens to the gut-associated lymphoid tissues (GALT), controlled release, and reduction of the gastrointestinal irritation caused by drugs. Beside this nanoparticles also offer other route of administrations. Various polymers have been used in the formulation of nanoparticles for drug delivery research to increase therapeutic benefit, while minimising side effects. This review article laid emphasis on various aspects of nanoparticles, their uptake, formulation, characterisation and applications of nanoparticles approach in delivery of drugs molecules and genes. He has worked on microspheres, microparticles, nanoparticles, porous pellets and controlled drug delivery systems.

show abstract

Inhalierte Vasodilatatoren

Cited by 22 publications

References 64 publications

The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy

The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy

Acute lung injury and acute respiratory distress syndrome

Nanoparticles: a boon for modernisation of drug delivery: a review

Contact Info

Product

Resources

About